UAB oncologists: HPV vaccine protects from cancer recurrence (w/ Video)

Mar 16, 2010

A vaccine designed to prevent cervical cancer also may protect females from post-surgical recurrence of the disease, according to researchers at the University of Alabama at Birmingham (UAB).

A new study shows that the Gardasil vaccine reduces the likelihood of (HPV)-related disease recurring after teen and adult already have had surgery to remove or certain pre-cancerous changes, said Warner Huh, M.D., an associate professor in the UAB Division of Gynecologic Oncology and lead presenter on the study.

The findings were announced March 15 at the annual meeting of the Society of Gynecological Oncologists in Chicago.

The study shows that Gardasil reduces by approximately 40 percent the chances that more cancer or pre-cancerous changes will occur in the cervix, vagina and vulva up to 3.8 years after a female has surgery for one of those conditions.

This video is not supported by your browser at this time.
Warner Huh, M.D., discusses the post-op protection found with HPV vaccine as it relates to cancer and pre-cancerous changes. Credit: UAB

Huh said the findings are important because they answer a question many women and their doctors have been asking — does an HPV vaccine help treat virus-related changes in the body after women have surgery to treat similar changes?

"Based on this study, the data is compelling and suggests it does help to treat virus-related changes," Huh said. "Knowing that Gardasil also may offer postoperative protection from recurrent disease will be crucial in follow-up care and overall health planning for teens and women."

The vaccine is approved to fight the four HPV strains believed to cause 70 percent of cervical cancers and more than 90 percent of genital warts

The study involved 17,622 women ages 15 to 26 from two clinical trials, some who were vaccinated and some who were not. Hundreds of study participants had surgery to remove cancer or certain pre-cancerous changes of the , vagina and vulva and to remove .

Huh said the results are encouraging because patients treated for HPV-related disease are known to be at higher risk for contracting the same disease post-operatively. Reducing the risk and need of a secondary procedure is an important step in improving women's care, he said.

Explore further: Gene marker may predict breast cancer response to tamoxifen

add to favorites email to friend print save as pdf

Related Stories

HPV vaccine reduces abnormal pap test results

Mar 10, 2008

In testing GARDASIL reduced abnormal Pap test results by 43 percent compared to women not given the vaccine, according new research. The findings show the approved anti-HPV agent appears to prevent the development of cell ...

New HPV vaccine under study

Nov 19, 2007

A new vaccine against nine of the most harmful strains of human papillomavirus is under study at the Medical College of Georgia.

FDA considers expanded use of HPV vaccine

Mar 20, 2008

Pharmaceutical manufacturer Merck & Co. Inc. said the U.S. Food and Drug Administration will consider expanding the use of its cervical cancer vaccine.

Women's cancer outcomes improved by surgical evaluation

Feb 12, 2009

Many women scheduled to undergo hysterectomy for pre-cancerous cell changes actually need a more comprehensive surgery, something they should discuss with a gynecologic oncologist, say researchers at the University of Alabama ...

HPV vaccines may reduce a wide range of genital diseases

Feb 05, 2010

High-coverage human papillomavirus (HPV) vaccinations among adolescents and young women may result in a rapid reduction of genital warts, cervical cell abnormalities, and diagnostic and therapeutic procedures, researchers ...

One in four California adolescent girls has had HPV vaccine

Feb 17, 2009

Less than two years after the HPV vaccine was approved as a routine vaccination for girls aged 11 and older, one-quarter of California adolescent girls have started the series of shots that protect against human papillomavirus, ...

Recommended for you

User comments : 0